Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03251729 · ClinicalTrials.gov registry record · Phase 4
Cerclage On LOw Risk Singletons: Cervical Cerclage for Prevention of Spontaneous Preterm Birth in Low Risk Singleton Pregnancies With Short Cervix
A Phase 4 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 4
- Development phase
- 93
- Enrollment target
NCT03251729: Completed Phase 4 study, sponsored by Thomas Jefferson University.
NCT03251729 is a Phase 4 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 93 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03251729, a Phase 4 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 93 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the efficacy of cervical cerclage in prevention of spontaneous preterm birth in singleton pregnancies with a short transvaginal cervical length (\<=25mm) and without prior spontaneous preterm birth
Primary Outcome
Incidence of spontaneous preterm birth less than 35 weeks
Interventions
- PROCEDURE Cervical cerclage
- DRUG Vaginal progesterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2017-09-22 |
| Est. Completion | 2024-02-20 |
| Phase | Phase 4 |
What the finished NCT03251729 record still lists
NCT03251729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Cervical cerclage is the first listed.
NCT03251729 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03251729 about?
NCT03251729 is a clinical study titled "Cerclage On LOw Risk Singletons: Cervical Cerclage for Prevention of Spontaneous Preterm Birth in Low Risk Singleton Pregnancies With Short Cervix". The aim of this study is to evaluate the efficacy of cervical cerclage in prevention of spontaneous preterm birth in singleton pregnancies with a short transvaginal cervical length (\<=25mm) and without prior spontaneous preterm birth
What is the current status of trial NCT03251729?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 93 participants. The study started on 2017-09-22. Estimated completion is 2024-02-20.
What interventions are being tested in trial NCT03251729?
The interventions under investigation include: Cervical cerclage (PROCEDURE), Vaginal progesterone (DRUG).
Who is sponsoring clinical trial NCT03251729?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03251729's enrollment target sits among peer trials
93 874th of 2000 higher than 1,125 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI